Expanding Rapid Ascertainment Network of Schizophrenia Families in Taiwan

This proposal responds to Request for Applications RFA-MH-08-131, which seeks applications that propose to enrich pre-existing resources for schizophrenia in the National Institute of Mental Health (NIMH) Human Genetics Initiative and to apply genomic methods to further the investigators understanding of the molecular etiology of the disorder. The overarching aims of this proposal are to quickly and cost-effectively ascertain a large sample of trio families affected by schizophrenia, and to discover causal variants for the disorder in the first family-based genome-wide association study (GWAS) of the disorder. In Taiwan, there is no such kind of policy to support this kind of GWAS study as it is a very expensive study, including collecting large family samples and genome-wide single-nucleotide polymorphism (SNP) scanning. The investigators, thus, collaborate with Professor Ming T, Tsuang and his entended subcontracted researchers to apply for this project. The investigators, the research team in Taiwan, will collect 3800 trio families (11400 subjects) of schizophrenia. Through additional ascertainment within this framework, the investigators will collect an aggregate sample with adequate power for detecting in a GWAS those variants that make even small contributions to the risk for the disorder.

The investigators will meet the overarching goals of this project by accomplishing several Specific Aims, as follows: 1) Rapidly ascertain schizophrenia trio families from Taiwanese clinical ascertainment sites; 2) Supplement NIMH Genetics Initiative collections by sending all clinical data and biomaterials to the appropriate repositories; 3) Assess the association of schizophrenia with a genome-wide panel of single-nucleotide polymorphisms (SNPs) and their constituent haplotypes; 4) Analyze quantitative schizophrenia phenotypes such as age at onset ; 5) Perform a genome-wide survey for copy-number variations related to schizophrenia; 6) Test for gene-gene interactions (epistasis); and 7) Test for gene-environment interactions, such as the well-established effect of season of birth.

Study Overview

• Status: Unknown
• Conditions: Schizophrenia
• Intervention / Treatment: Other: No intervention would be provided in this research

• Study Type: Observational
• Enrollment (Anticipated): 600

Contacts and Locations

Study Locations

• Taiwan
  • Taichung, Taiwan
    • Recruiting
    • China Medical University Hospital
    • Contact: Hsien-Yuan Lane

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 16 years to 90 years (Child, Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

Schizophrenia patients and their biological parents

Description

Inclusion Criteria:

• clinical diagnosis of schizophrenia and their parents, and parents are still alive

Exclusion Criteria:

• person with Mental Retardation
• persons with epilepsy
• alcohol or substance abuse combined
• in combination with other organic brain damage syndrome

Study Plan

How is the study designed?

Design Details

• Observational Models: Family-Based

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Schizophrenia Family	Other: No intervention would be provided in this research; No intervention would be provided in this research,but need to draw blood

Collaborators and Investigators

• Sponsor: China Medical University Hospital
• Collaborators: National Taiwan University Hospital
• Investigators: Study Director: Hsien-Yuan Lane, China Medical University Hospital

Study record dates

Study Major Dates

• Study Start: October 1, 2010
• Primary Completion (Anticipated): December 1, 2013
• Study Completion: December 7, 2022

Study Registration Dates

• First Submitted: November 24, 2010
• First Submitted That Met QC Criteria: November 26, 2010
• First Posted (Estimate): November 29, 2010

Study Record Updates

• Last Update Posted (Estimate): December 1, 2010
• Last Update Submitted That Met QC Criteria: November 30, 2010
• Last Verified: October 1, 2010

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Mental Disorders; Schizophrenia Spectrum and Other Psychotic Disorders; Schizophrenia
• Other Study ID Numbers: DMR99-IRB-214

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No